Darlin Lantigua joins Dynamic42 in the United States as Field Application Specialist
Dynamic42 is pleased to welcome Darlin Lantigua as our new Field Application Specialist for the United States. With his strong scientific background in tissue engineering and assay development, Darlin will play a leading role in expanding Dynamic42’s presence in the USA and helping our local customer base implement advanced organ-on-chip applications.
Darlin holds a Master of Science in Biomedical Engineering and Biotechnology and a Bachelor of Science in Biological Sciences from the University of Massachusetts Lowell. He brings more than six years of research experience in biomaterials, tissue engineering, diagnostics, and cell culture, and has contributed to the development of innovative diagnostic technologies, including point-of-care devices for infectious disease detection, therapeutic drug monitoring, and sepsis diagnostics. He is a co-author of multiple peer-reviewed scientific publications and a contributor to patent applications related to diagnostics and biomaterials. Most recently, Darlin worked as a Senior Researcher supporting assay development, performance characterization, and data analysis for novel immunoassay technologies.
At Dynamic42, Darlin will serve as a Field Application Specialist, supporting Dynamic42 customers and partners throughout the USA. He will provide technical guidance, training, and application support for our DynamicOrgan® organ-on-chip platform. Working closely with researchers to facilitate the successful implementation of our advanced in vitro models in their studies, he will support Dynamic42’s presence and customer relationships across the U.S. market.
I am excited to join Dynamic42 and contribute to the advancement of organ-on-chip technology in the United States. Throughout my career, I have been passionate about developing and applying innovative biomedical technologies that improve research outcomes. I look forward to working closely with researchers, supporting their scientific goals, and helping expand the adoption of more predictive and human-relevant research models.